Abstract: The 3?-5? exonuclease, Dis3l2, is responsible for the decay of uridylated pre-let-7 miRNA. Biochemical reconstitution assays revealed that 3? oligouridylation stimulates Dis3l2 activity in vitro, and knockdown of Dis3l2 in mouse embryonic stem cells leads to the stabilization of pre-let-7 miRNA. These Dis3l2-depleted stem cells displayed elevated expression of pluripotency genes and delayed differentiation. The present disclosure establishes 3? oligouridylation as an RNA decay signal for Dis3l2 and identifies the first physiological RNA substrate of this exonuclease.

Abstract: A method comprising obtaining a donor composition from a donor subject wherein the donor composition comprises a plurality of adult stem cell types; obtaining a receiver composition from a receiver subject wherein the receiver composition comprises a plurality of adult stem cell types; and co-culturing the donor composition and receiver composition wherein co-culturing comprises contacting the receiver composition a cell-free portion of the donor composition to produce a restored composition. Pharmaceutical compositions comprising a restored composition.

Abstract: A method for in vitro obtaining human retinal progenitors, includes the steps of (i) placing an adherent culture of human pluripotent stem cells in a pro-neural medium; and (ii) maintaining this culture in the pro-neural medium until the appearance of pigmented cells and/or of neuroepithelial-like structures. Additional steps can be performed to obtain RPE cells and/or precursors of the neural retina.

Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.

Abstract: Disclosed are methods for isolating, cultivating, and/or cells including regulatory T cells (Tregs). The methods typically include cultivating cells including Tregs in a culture media comprising a ligand for programmed cell death receptor (PD-1) conjugated to a solid support. Suitable ligands may include PD-L1 and suitable solid supports may include magnetic or paramagnetic beads where the methods further include removing the PD-L1/bead conjugates after the Tregs have been isolated, cultured, and/or expanded.

Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.

Abstract: The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors.

Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiating an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell, produced by using the medium composition into a chondrocyte. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into chondrocytes.

Abstract: The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.

Abstract: This invention provides a method for testing a factor for cardiogenicity which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence and absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and measuring the differentiation in the presence and absence of the factor. This invention also provides a method for identifying a cardiogenic factor, which comprises differentiating human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor wherein the human embryonic stem (hES) cells are cultured under a serum free condition comprising co-culture in the presence of END-2 cells or serum-free extracellular medium therefrom, and identifying the factor that affects the differentiation of human embryonic stem (hES) cells to cardiomyocytes in the presence or absence of the factor.

Abstract: This disclosure is in the area of research and therapeutics. In certain embodiments, it provides methods to assist in the purification of cell mixtures, e.g., cardiomyocytes, using molecular beacons targeting cell-type specific RNA, e.g. mRNA.

Abstract: Provided is a composition for promoting hair growth comprising platelet-derived growth factor-D (PDGF-D)-treated adipose-derived stem cells (ASCs) as an active ingredient, and more particularly, a therapeutic agent for hair loss comprising ASCs with increased proliferation and migration by PDGF-D and increased expression and secretion of a growth factor as an active ingredient. PDGF-D-treated ASCs have improved hair regenerative potential through the increases in proliferation, migration and growth factor secretion and thus are useful for a therapeutic agent for hair loss or a cosmetic for preventing hair loss.

Abstract: Described are methods for differentiating mammalian pluripotent stem cells towards a population of cells that can self-organize into vascular networks in vitro when harvested cells of the present invention are embedded into a hydrophilic matrix such as a hydrogel.

Abstract: Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.

Abstract: Object An object of the present invention is to provide a highly stable FVHO preparation and a low-hygroscopicity dried FVHO preparation. Means for achieving the object A method for producing a FVHO preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, D-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried FVHO preparation, comprising a step of allowing Bicine to coexist.

Abstract: This disclosure concerns recombinant host organisms genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins that allow for and/or improve the production of PUFAs in the host organism. The disclosure also concerns methods of making and using such organisms as well as products obtained from such organisms.

Abstract: A secretion signal peptide sequence (SP) in combination with a cleavage inhibition sequence (CIS) fused to a structural gene sequence in a recombinant expression system can be used to express a full length protein with an SP in a cell. Such a fusion protein may be purified to homogeneity from a membrane fraction of the cell. The SP in combination with the CIS is a protein transduction domain that exhibits superior intracellular protein transduction efficiency when the SP precedes the CIS in a N to C-terminus direction.

Abstract: The invention provides a polypeptide possessing anti-hypertrophic activity in a cardiac myocyte, wherein the polypeptide is a mutant variant derived from wild-type PDE3A1 protein and wherein the wild-type PDE3A1 protein has the amino acid sequence given in SEQ ID NO:1 at amino acid position 146 to 1141.

Abstract: The present disclosure provides compositions and methods for binding and/or cleaving a single stranded target nucleic acid. Subject compositions include a Cas9 polypeptide, a guide nucleic acid, and a PAMmer. A subject PAMmer is a single stranded oligonucleotide having a protospacer adjacent motif (PAM) sequence and at least one of: a specifity segment positioned 5? of the PAM sequence, and an orientation segment positioned 3? of the PAM sequence. In some embodiments, the Cas9 polypeptide is a variant Cas9 polypeptide having reduced nuclease activity relative to a corresponding wild type Cas9 polypeptide. In some cases, methods of binding are for visualizing single stranded target nucleic acids using a detectable label. In some cases, methods of binding are for isolating, collecting, and/or analyzing at least one of: (i) bound single stranded target nucleic acids; and (ii) polypeptides associated with bound single stranded target nucleic acids.

Abstract: The present invention relates to methods for degrading or converting a cellulosic material and for producing a substance from a cellulosic material.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and polynucleotides encoding the polypeptides, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: Provided are isolated polypeptides having alpha-amylase activity, catalytic domains, carbohydrate binding domains and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding domains.

Abstract: The present invention is directed to the construction of prototrophic, cellulo lytic strains of Saccharomyces cerevisiae with tethered and secreted cellulases and selection-based improvement of growth on cellulose by these strains. In some embodiments, host cells of the invention are able to produce ethanol using crystalline cellulose as a sole carbon source.

Abstract: The invention relates to novel variants of fungal endoglucanases, their production and means for their production. Especially the invention relates to variants of Acremonium thermophilum Cel45A. The invention further relates to enzyme preparations and detergent compositions comprising at least one novel variant endoglucanase as well as to processes for treating cellulosic material therewith. The novel variant endoglucanase polypeptides have improved performance in textile applications, especially in biofinishing and biostoning, and in detergent applications, in fabric care and color maintenance, especially in prevention and removal of fuzz and pills, in color care and revival.

Abstract: The invention relates to a variant polypeptide having lactase activity. The invention also relates to a nucleic acid sequence encoding such a variant polypeptide, to a nucleic acid construct comprising said nucleic acid sequence, to a recombinant expression vector comprising said nucleic acid construct and to a recombinant host cell comprising said expression vector. Further, the invention relates to a method for producing a lactase variant via use of such a host cell. Also, the invention relates to a method of producing a lactase polypeptide variant. The invention further relates to a composition comprising a lactase variant, to use of such a lactase variant or to the use of a lactase variant-containing composition in the preparation of a dairy product, to a process for the production of a dairy product and to the resulting dairy product.

Abstract: The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: Methods, systems, and devices are disclosed for capturing, concentrating, and isolating molecules in a fluid.

Abstract: A method of extracting DNA from a biological sample includes the steps of freezing a biological sample; mechanically breaking down the sample to produce a processed sample; mixing the processed sample with a lysis solution; and cycling the mixture through a series of pressure fluctuations to produce a resulting lysate. The method may further include the steps of exposing the lysate to a material that binds to DNA present in the sample and collecting the DNA from the sample using an elution solution. An apparatus for practicing the method includes a first segment for mechanically breaking down the sample; a second segment for pressurizing a mixture of the processed sample and lysis solution to produce a lysate; and wherein the first segment is fluidly coupled to the second segment. The apparatus may also include a third segment in which the lysate is exposed to the binding material.

Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

Abstract: Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.

Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of coleopteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in coleopteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of coleopteran pests, and the plant cells and plants obtained thereby.

Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.

Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-21 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects with liver conditions, such as liver cancer.

Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.

Abstract: A pharmaceutical composition for preventing and treating endocrine disrupting chemicals-induced diseases and a treating method using the same. Since the composition has an effect of decreasing lipid accumulation caused by endocrine disrupting chemicals, for example, persistent organic pollutants (POPs) including polychlorinated biphenyl and the like and can improve insulin resistance caused by the POPs through reduction of insulin receptor substrate 1 (IR1), the composition can be helpfully used for treating diseases including obesity, insulin resistance, and the like caused by the endocrine disrupting chemicals. Further, according to the present disclosure, the composition has an effect of excreting the endocrine disrupting chemicals.

Abstract: Provided is a method of separating senescent cells from a sample including the senescent cells, and a method of removing senescent cells from a sample or a subject including the senescent cells.

Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.

Abstract: The present invention relates to a multifunctional short interfering nucleic acid (siNA) having a structure of Formula MF-III: wherein each X, X?, Y, and Y? is independently an oligonucleotide of length about 15 nucleotides to about 50 nucleotides; X comprises a nucleotide sequence that is complementary to a nucleotide sequence present in region Y?; X? comprises a nucleotide sequence that is complementary to a nucleotide sequence present in region Y; one or more of X, X?, Y, and Y? is independently complementary to a first, second, third, or fourth target sequence, respectively, or a portion thereof; and W represents a nucleotide or non-nucleotide linker that connects sequences Y? and Y, wherein the siNA directs cleavage of the first, second, third, and/or fourth target sequence via RNA interference.

Abstract: The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.

Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (GHR).

Abstract: The present invention relates to the field of gene therapy, more specifically to oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell.

Abstract: Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.

Abstract: The present invention relates generally to constructs and their use in gene expression or gene regulation assays. More particularly, the present invention provides expression vectors and/or reporter vectors providing kinetics of protein expression with improved temporal correlation to promoter activity. Even more particularly, the invention provides expression vectors comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding a RNA element that modulates the stability of a transcript corresponding to the transcribable polynucleotide. The present invention provides, inter alia, novel vectors, useful for identifying and analysing cis- and trans-acting regulatory sequences/factors as well as vectors and genetically modified cell lines or organisms that are particularly useful for drug screening and drug discovery.

Abstract: The present invention relates to a method of producing HPV pseudovirions in plant cells, the plant produced pseudovirions per se, a neutralization assay using the plant produced pseudovirions and pharmaceutical compositions comprising the plant produced pseudovirions.

Abstract: MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT.

Abstract: The present invention relates to a plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, wherein the plant has a reduced level, reduced activity or complete absence of DMR6 protein as compared to a plant that is not resistant to the said pathogen, in particular organisms of the Fungi or the phylum Oomycota. The invention further relates to a method for obtaining a plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, comprising reducing the endogenous level or activity of DMR6 protein in the plant. In addition, the invention relates to the use of a DMR6 promotor for providing disease resistant plants.

Abstract: Rice is described that is tolerant/resistant to a plurality of herbicides, for example, ACCase and HPPD inhibitors. Use of the rice for weed control and methods of producing tolerant/resistant rice are also described.